Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Overcoming barriers in cancer care for gender minorities

Nature Reviews Urology (2024)Cite this article

Subjects

As the population of gender minorities grows in the setting of rising incidence of cancers globally, health-care professionals and institutions must be prepared to provide inclusive care. Individual-level training as well as institutional-level efforts on gender identity data collection and creation of inclusive clinical spaces could help mitigate health-care disparities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thorne, N., Yip, A. K.-T., Bouman, W. P., Marshall, E. & Arcelus, J. The terminology of identities between, outside and beyond the gender binary - a systematic review. Int. J. Transgend. 20, 138–154 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kcomt, L., Gorey, K. M., Barrett, B. J. & McCabe, S. E. Healthcare avoidance due to anticipated discrimination among transgender people: a call to create trans-affirmative environments. SSM Popul. Health 11, 100608 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Brown, J. et al. Prevalence of cancer risk factors among transgender and gender diverse individuals: a cross-sectional analysis using UK primary care data. Br. J. Gen. Pract. 73, e486–e492 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cancer risk in the transgender community. Lancet Oncol. 16, 999 (2015).

  5. Jackson, S. S. et al. Cancer stage, treatment, and survival among transgender patients in the United States. J. Natl Cancer Inst. 113, 1221–1227 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kamen, C. S. et al. Sexual orientation and gender identity data collection in oncology practice: findings of an ASCO survey. JCO Oncol. Pract. 18, e1297–e1305 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Leone, A. G. et al. Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology. ESMO Open 8, 101578 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moloney, C. et al. Assessing the quality of care delivered to transgender and gender diverse patients with cancer in ireland: a case series. Oncologist 26, e603–e607 (2021).

    Article  PubMed  Google Scholar 

  9. Mizock, L. et al. The transgender awareness webinar: reducing transphobia among undergraduates and mental health providers. J. Gay Lesbian Ment. Health 21, 292–315 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hoag Family Cancer Institute, Newport Beach, CA, USA

    David J. Benjamin

  2. Division of Hematology/Oncology, Department of Medicine, UC Irvine Medical Center, Orange, CA, USA

    Omid Yazdanpanah & Arash Rezazadeh Kalebasty

Authors
  1. David J. Benjamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omid Yazdanpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arash Rezazadeh Kalebasty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Benjamin.

Ethics declarations

Competing interests

D.J.B. declares a consulting or advisory role at Astellas, Eisai and Seagen; speakers’ bureau at Merck; and travel and accommodations from Merck. A.R.K. declares stock and other ownership interests from ECOM Medical; a consulting or advisory role from Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau at Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding from Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and/or expenses from Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. O.Y. declares no competing interests.

Additional information

Related links

More Inclusive Healthcare: https://moreinclusivehealthcare.com/

National LGBTQIA + Health Education Center: https://www.lgbtqiahealtheducation.org/resources/in/transgender-health/

Pew Research Center: https://www.pewresearch.org/short-reads/2022/06/07/about-5-of-young-adults-in-the-u-s-say-their-gender-is-different-from-their-sex-assigned-at-birth/

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benjamin, D.J., Yazdanpanah, O. & Rezazadeh Kalebasty, A. Overcoming barriers in cancer care for gender minorities. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00894-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41585-024-00894-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer